INmune Bio GAAP EPS of -$1.86 misses by $0.11, revenue of $0.05M misses by $0.01M
Source: SeekingAlpha
2026-03-30 16:02:17 ET
More on INmune Bio
- INmune Bio Inc. (INMB) Discusses XPro1595 Phase II MINDFuL Results and Registrational Strategy in Alzheimer's Disease Transcript
- INmune Bio Inc. (INMB) Discusses MissionEB Phase III Trial and CORDStrom as a Disease-Modifying Therapy for RDEB Transcript
- INmune Bio FY 2025 Earnings Preview
- Quant snapshot: J. Jill, AngioDynamics leads strong buys as INmune Bio, Terrestrial Energy lag
- Seeking Alpha’s Quant Rating on INmune Bio
Read the full article on Seeking Alpha
For further details see:
INmune Bio GAAP EPS of -$1.86 misses by $0.11, revenue of $0.05M misses by $0.01M
INmune Bio Inc.
NASDAQ: INMB
INMB Trading
12.2% G/L:
$1.655 Last:
3,518,288 Volume:
$1.59 Open:
INMB Latest News
May 15, 2026 08:00:00 am
INmune Bio Publishes Phase 2 MINDFuL Trial Results in NPJ Dementia, Advancing the XPro(TM) Platform
May 14, 2026 08:00:00 am
INmune Bio Receives FDA Fast Track Designation for XPro1595 in Early Alzheimer's Disease
INMB Stock Data
$100,001,939
20,608,626
3.69%
19
N/A
Biotechnology & Life Sciences
Healthcare
US
Boca Raton
